Clinical trials: Immunologic Deficiency Syndromes
HIV Testing, HIV Infections
Near Patient Study of the OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in Oral Fluid and Fingerstick Whole Blood
Point-of-care (POC) tests for HIV are easy to use, rapid and provide accurate results while the patient is still in-front of a healthcare provider (HCP).
- Trial name
- NCT04810559
- Testing
- OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test
- Where
- 4 sites in Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
HIV Infections
Use of Amphetamine-type Stimulants & Its Relationship With HIV Incidence and Antiretroviral Adherence Among MSM and TG
There are two stages in the study. In Stage 1, 2000 Thai MSM, MSW and TGW/TGSW will be screened at the Thai Red Cross Anonymous Clinic (TRCAC) or Besides walk-in clients of TRCAC, potential participants could be referred to TRCAC…
- Trial name
- NCT03198962
- Where
- Thailand
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
HIV Infections
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
To evaluate the safety, tolerability and immunogenicity in humans of the APL-400-047 vaccine when administered intramuscularly by needle and syringe at 1 of 3 doses or by Biojector at the intermediate dose.
- Trial name
- NCT00001088
- Testing
- APL 400-047, Bupivacaine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
HIV Prevention and PrEP Intervention for SGM Adolescents and Parents: "Hey, Friend"
In this 24-month pilot study, we will conduct the preparation phase of a multiphase optimization strategy (MOST) to develop a culturally appropriate (for Deep South contexts, to be adolescent friendly, and to be acceptable to…
- Trial name
- NCT04846946
- Testing
- Hey, Friend
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV Infections
Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
This trial will study a prime-boost vaccine approach designed mainly to induce cell-mediated immune (CTL) responses.
- Trial name
- NCT00902824
- Testing
- ADVAX, TBC-M4
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infection
Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population…
- Trial name
- CohMSM (NCT02626286)
- Testing
- HIV quarterly global care
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults
Vaccines have been very successful in preventing viral infections such as hepatitis B and the measles. Viral vaccines work by causing a person's immune system to make cells that will work against the virus.
- Trial name
- NCT00623753
- Testing
- EnvDNA, PolyEnv1, EnvPro
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
HIV Infections
Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates
The purpose of the study is to study the effects of BMS-955176 on the single-dose PK parameters of probe substrates caffeine, metoprolol, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin
- Trial name
- NCT02578277
- Testing
- CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV/AIDS, Myocardial Infarction
Inflammation and Cardiovascular Health in Women
Systemic immune activation and inflammation are believed to play a significant role in the development and clinical course of myocardial infarction (MI).
- Trial name
- NCT04224181
- Testing
- Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
HIV Infections
Partners PrEP Program
Through close collaboration with the Ugandan Ministry of Health, the investigators plan to provide PrEP for HIV-negative members of HIV serodiscordant couples by launching PrEP delivery within 12 public ART clinics in Kampala…
- Trial name
- PPP (NCT03586128)
- Testing
- PrEP, ART
- Where
- Uganda
- Volunteers
- 1,381 people, healthy volunteers welcome
- Sponsor
- University of Washington
Pharmacokinetics, Bioavailability
TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation
The purpose of this study is to evaluate how much and how fast a single, oral, daily 25 mg dose of TMC278 is absorbed into the body when administered as a solution, suspension, granules, or a tablet.
- Conditions
- Pharmacokinetics, Bioavailability, HIV-1
- Trial name
- NCT00812292
- Testing
- TMC278
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
The purpose of this study is to evaluate the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with an experimental modified vaccinia HIV vaccine (MVA) in HIV uninfected adults.
- Trial name
- NCT00574600
- Testing
- SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine
- Where
- 4 sites in United States, South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Opioid Use Disorder, HIV Infections
Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington
The investigators will implement a non-randomized observational clinical trial that will include a pop-up clinic for women who inject drugs (WWID) near venues for exchange sex and drug use in north Seattle.
- Conditions
- Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea
- Trial name
- NCT06187064
- Testing
- Mobile Van Clinic
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
Quality of Life, Depression and Sexual Function in Men Living With HIV
This observational case-control study evaluates quality of life, depressive symptoms, and sexual function in heterosexual men living with HIV who are receiving effective combination antiretroviral therapy and have achieved…
- Trial name
- NCT07376239
- Where
- Turkey (Türkiye)
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Kocaeli University
HIV/AIDS
PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women
The investigators will first develop, tailor, and refine PrEP My Way for use with young women in Kisumu, Kenya (Aim 1). The design firm will use a client-centered, iterative approach, involving up to 15 individual interviews and…
- Trial name
- NCT04408729
- Testing
- PrEP My Way
- Where
- Kenya
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
HIV Infections
A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
To determine the safety and immunogenicity of 200 mcg MN rgp160 vaccine (Immuno-AG) versus placebo, administered on two immunization schedules to healthy volunteers.
- Trial name
- NCT00001037
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Malaria
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults
Despite the clinical significance of potential interactions between antimalarials and antiretrovirals, no drug interaction studies have been published and there is an urgent need to address this gap in current knowledge.
- Trial name
- SEACAT 2_4_2 (NCT00869700)
- Testing
- Artemether/Lumefantrine
- Where
- South Africa
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
HIV Infections
Rapid HIV Testing for Emergency Department Patients
The purpose of this study is to test data collection options in emergency departments (EDs) and to enhance ED patient awareness of the risk of HIV infection.
- Trial name
- NCT00676481
- Testing
- HIV risk education
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761
This is a single-center, randomized, two part, open-label, crossover study in healthy adult subjects to assess the effect of up to three formulations on the relative bioavailability of GSK2248761 100mg administered with and…
- Trial name
- NCT01031472
- Testing
- GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers
The purpose of this study is to evaluate the safety and tolerability of plasmid DNA and recombinant MVA (Modified Vaccinia Virus Ankara) in a prime-boost regimen.
- Trial name
- NCT01371175
- Testing
- DNA.HIVA, MVA.HIVA
- Where
- 2 sites in Kenya, United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.